Display options
Cite
Bosso JA, Haines ML, Gomez J. Stable susceptibility to aminoglycosides in an age of low level, institutional use. Infect Dis Ther. 2013;2(2):209-15doi: 10.1007/s40121-013-0016-4.
Bosso, J. A., Haines, M. L., & Gomez, J. (2013). Stable susceptibility to aminoglycosides in an age of low level, institutional use. Infectious diseases and therapy, 2(2), 209-15. https://doi.org/10.1007/s40121-013-0016-4
Bosso, John A, et al. "Stable susceptibility to aminoglycosides in an age of low level, institutional use." Infectious diseases and therapy vol. 2,2 (2013): 209-15. doi: https://doi.org/10.1007/s40121-013-0016-4
Bosso JA, Haines ML, Gomez J. Stable susceptibility to aminoglycosides in an age of low level, institutional use. Infect Dis Ther. 2013 Dec;2(2):209-15. doi: 10.1007/s40121-013-0016-4. Epub 2013 Oct 22. PMID: 25134483; PMCID: PMC4108105.
Copy Download .nbib Format: NLM
Share it on

Infect Dis Ther. 2013 Dec;2(2):209-15. doi: 10.1007/s40121-013-0016-4. Epub 2013 Oct 22.

Stable susceptibility to aminoglycosides in an age of low level, institutional use.

Infectious diseases and therapy

John A Bosso, Martha L Haines, Juanmanuel Gomez

Affiliations

  1. South Carolina College of Pharmacy, Charleston, SC, 29425, USA, [email protected].

PMID: 25134483 PMCID: PMC4108105 DOI: 10.1007/s40121-013-0016-4

Abstract

INTRODUCTION: The use of aminoglycosides has decreased dramatically over several decades in the United States due to the introduction of safer Gram-negative agents. This study was conducted to assess possibly changing aminoglycoside susceptibility rates between 2006 and 2012 and in reference to 1992 use in the context of aminoglycoside use volume.

METHODS: Quarterly adult use of amikacin, gentamicin and tobramycin were determined from the Medical University of South Carolina Medical Center, Charleston, South Carolina, USA, pharmacy drug use database and expressed as total aminoglycoside defined daily doses per 1,000 patient days for the years 1992 and 2006 through 2012. Annual susceptibility of Pseudomonas aeruginosa, Escherichia coli, and Klebsiella pneumoniae, for the years 1992, 2006, and 2008 through 2012 were retrieved from our hospital's clinical microbiology database (duplicate isolates were excluded). Quarterly and annualized aminoglycoside usage rates were compared to the other years of interest. Likewise, susceptibility rates of the target organisms to each aminoglycoside were also compared across the same timeframe.

RESULTS: While total use of aminoglycosides decreased slightly from 1992 to 2006, it increased by about 40% between 2006 and 2008 and then stabilized. Changes in susceptibility rates between 1992 and 2006 were all ≤±9% with the exception of K. pneumoniae susceptibility to amikacin (-17%). Changes in susceptibility from 1992 to 2012 were also all ≤±9%. Tobramycin remained the most active versus P. aeruginosa (% susceptible = 90), while amikacin remained most active versus E. coli and K. pneumoniae (% susceptible = 98 and 98, respectively).

CONCLUSION: With low level use of aminoglycosides in our institution over the past 2 decades, the susceptibility of key Gram-negative pathogens has remained relatively stable, preserving these agents as potential alternative therapies as resistance arises to other frequently used antibiotics.

References

  1. Arch Intern Med. 2008 Nov 10;168(20):2254-60 - PubMed
  2. J Infect Dis. 1980 Mar;141(3):338-45 - PubMed
  3. Surg Infect (Larchmt). 2009 Dec;10(6):563-70 - PubMed
  4. J Antimicrob Chemother. 2009 Feb;63(2):246-51 - PubMed
  5. Infect Control Hosp Epidemiol. 2013 Jul;34(7):730-9 - PubMed
  6. Am J Med. 1985 Jul 15;79(1A):1-7 - PubMed
  7. Appl Microbiol Biotechnol. 2006 Mar;70(2):140-50 - PubMed
  8. J Clin Microbiol. 2007 Apr;45(4):1339-42 - PubMed
  9. N Engl J Med. 2005 Jan 27;352(4):380-91 - PubMed
  10. Infect Control Hosp Epidemiol. 2012 Jun;33(6):594-601 - PubMed
  11. Antimicrob Agents Chemother. 2005 May;49(5):2137-9 - PubMed
  12. Diagn Microbiol Infect Dis. 2007 Feb;57(2):201-5 - PubMed
  13. Infect Control Hosp Epidemiol. 2010 Nov;31 Suppl 1:S51-4 - PubMed
  14. Antimicrob Agents Chemother. 1991 Jul;35(7):1284-90 - PubMed
  15. Antimicrob Agents Chemother. 2010 May;54(5):2010-6 - PubMed
  16. Ann Intern Med. 1984 Feb;100(2):219-22 - PubMed
  17. Infect Control Hosp Epidemiol. 2008 Nov;29(11):996-1011 - PubMed
  18. Antimicrob Agents Chemother. 2011 Jun;55(6):2528-31 - PubMed
  19. Diagn Microbiol Infect Dis. 2009 Dec;65(4):414-26 - PubMed

Publication Types